Critical reviews of economic analyses in order to make health care decisions for cancer

Annals of Oncology

Volumn 9, Issue 11, 1998, Pages 1167-1172

  Neymark, N ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Cost analysis; Economic evaluation; Meta analysis; Secondary analysis; Transferability

Indexed keywords

CANCER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EUROPE; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; META-ANALYSIS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS;

EID: 0031773060     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008450824325     Document Type: Review

References (26)

1. Birch S. As a matter of fact: Evidence-based decision-making unplugged. Health Econ 1997; 6: 647 59.
2. Maynard A. Evidence-based medicine: An incomplete method for informing treatment choices. Lancet 1997; 349: 126 8.
3. Sackett D, Rosenberg W. On the need for evidence based medicine. Health Econ 1995; 4: 249 54.
4. Badia X, Nocea G, Rovira J. Differences in the methodology and data of economic evaluations of a health programme. The case of hepatitis B vaccination programmes in Spain. PharmacoEconomics 1997; 11: 175 83.
5. Jefferson T, Dimicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ 1994; 3: 25-37.
6. Carrere MO, Lamouliatte H. Ruszniewski P. Is Helicobacter pylori eradidation a cost-effective treatment of duodenal ulcer disease? PharmacoEconomics 1997: 11: 216-24.
7. Jefferson T, Mugford M, Gray A et al. An exercise on the feasibility of carrying out secondary economic analyses. Health Econ 1996; 5: 155-65.
8. Rigby K, Silagy C, Crockett A. Health economic reviews. Are they compiled systematically? Int J Technol Assess Health Care 1996; 12: 450 9.
9. Freemantle N, Mason J. Publication bias in clinical trials and economic analyses. PharmacoEconomics 1997; 12: 10 6.
10. Bryan S. Brown J. Extrapolation of cost-effectiveness information to local settings. HERG Discussion paper no. 17, Brunel University 1997.
11. Neymark N. Assessing the Economic Value of Anticancer Therapies. Heidelberg: Springer 1998.
12. Coyle D, Davies L, Drummond M. Trials and tribulations. Emerging issues in designing economic evaluations alongside clinical trials. Intl J Techn Assess Health Care 1998; 14: 135-44.
13. Neymark N, Kiebert W, Torfs K et al. Methodological and statistical issues of quality of life and economic evaluation in cancer clinical trials. Eur J Cancer 1998; 34: 1317 33.
14. Lau J, Ioannidis J, Schmid C. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-6.
15. Naylor D. Meta-analysis and the meta-epidemiology of clinical research. BMJ 1997; 315: 617-9.
16. Kesteloot K, Pocceschi S, Van der Schueren E. Reimbursement for radiotherapy treatment in the EU countries: How to encourage efficiency, quality and access? Radiother Oncol 1996; 38: 187 94.
17. Bredeson C, Malcolm J, Davis M et al. Cost analysis of the introduction of PBPC for autologous transplantation: Effect of switching from hone marrow (BM) to peripheral blood progenitor cells. Bone Marrow Transplant 1997; 20: 889 96.
18. Smith T, Hillner B, Schmitz N et al. Economic analysis of a randomized trial to compare filgrastim-mobilized peripheral-blood-progenitor-cell transplantation and autologous bone marrow transplantation in patients with relapsed Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10.
19. Fervers B, Spath HM, Philip T. Intégration des critères économiques dans les recommendations pour la pratique clinique en cancérologie. Bull Cancer 1998; 85: 272-80.
20. Drummond MF. Jefferson T. Guideline for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275 83.
21. Udvarhelyi IS, Colditz GA, Rai A et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med 1993; 116: 238-44.
22. Cook D, Guyatt G, Laupacis A et al. Rules of evidence and clinical recommendations on the use of anti-thrombotic agents. Chest 1992; 102 (Suppl): 305S-11S.
23. Cook T. Campbell D. Quasi-Experimentation: Design and Analysis of Field Settings. Boston: Houghton Mifflin 1979.
24. Todd C. WOSCOPS economic model results: Applicable to other countries, PharmacoEconomics Outcomes News, no. 171 1998.
25. Menzin J, Oster G, Davies L. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Techn Assess Health Care 1996: 12: 52-61.
26. Weistein M, Fineberg H. Elstein A et al. Clinical Decision Analysis. Philadelphia. PA: Saunders 1980.